Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.

ABSTRACT:

Objective

The objective of this study was to evaluate the efficacy and safety of s.c. secukinumab 300 mg combined with standard of care (SoC) in adult patients with active LN.

Methods

The core study was a phase III randomized, placebo-controlled, double-blind study (planned duration: 104 weeks) of patients with active LN. Eligible patients were randomized to receive secukinumab 300 mg or placebo for the first 4 weeks, followed by a monthly maintenance dose, with all patients receiving a SoC background regimen. Patients completing the 104-week treatment of the core study were eligible for an open-label extension study (planned duration: up to 260 weeks) to receive secukinumab 300 mg every 4 weeks. The primary end point of the core study was the proportion of patients achievin

SUBMITTER: Zhao MH 

PROVIDER: S-EPMC12862366 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature